End-stage liver disease (ESLD) resulting from various causes of chronic liver disease is one of the leading causes of premature mortality in the United States. For these patients, liver transplantation (LTx) can improve survival and restore health. One of the most common and serious complications in patients with ESLD undergoing LTx is acute and chronic kidney disease. We have recently demonstrated that many (50%) of LTx recipients have evidence of serious kidney damage known as acute tubular necrosis (ATN) and nephrosclerosis (NSc). In particular, essentially all of the patients who had ATN at the time of LTx developed chronic kidney disease (CKD) within 4 months of LTx. In this application, we ask the following clinically relevant questions: (1) Is the high prevalence of ATN and NSc shown in our study generalizable to LTx recipients at large;(2) can these histologic changes be diagnosed by non-invasive markers;and (3) does incorporating the renal histology information into patient management improve patient outcome following LTx? In order to address these questions, we propose to undertake the following studies.
In AIM1, we will evaluate renal histology as a predictor of post-LTx renal function. In a well-established multicenter prospective cohort of LTx recipients, we will perform intraoperative renal biopsies at the time of LTx and (1) determine the prevalence of ATN and NSc in LTx recipients and (2) measure the impact of ATN and NSc on kidney function 1 year after LTx.
In AIM2, we will examine urinary biomarkers as a correlate of ATN in ESLD patients, based on our preliminary data that urinary biomarkers such as 1- microglobulin, neutrophil gelatinase-associated lipocalin, kidney injury molecule-1 and microalbumin correlate with renal histology, specifically ATN. Individual studies of AIM2 will (1) develop and validate a mathematical model to diagnose ATN in LTx recipients based on a panel of urinary biomarkers and (2) determine the clinical significance of these biomarkers by correlating them with future kidney function.
In AIM3, we will conduct a pilot trial for individualized medical management ('renal sparing protocol') in LTx recipients utilizing information obtained from the renal biopsy. Taken together, these studies will advance knowledge about the renal abnormalities in ESLD and LTx patients and help optimize patient outcomes by providing valid, accurate and practical clinical tools with which to identify patients at risk of serious morbidity and mortality and provide effective, individualized intervention.

Public Health Relevance

The goal of this research is to understand the nature of kidney disease that occurs in patients with cirrhosis undergoing liver transplantation. We will accomplish this goal by obtaining and analyzing biopsies of the kidney and urine samples in patients undergoing liver transplantation and correlating their results with kidney function after transplantation. We will also conduct a pilot trial to evaluate whether individualized care of live transplant recipients can help improve their kidney function.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Kidney, Nutrition, Obesity and Diabetes (KNOD)
Program Officer
Sherker, Averell H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Udompap, Prowpanga; Mannalithara, Ajitha; Heo, Nae-Yun et al. (2016) Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection. J Hepatol 64:1027-32
Allen, Alina M; Kim, W Ray; Larson, Joseph J et al. (2016) The Epidemiology of Liver Diseases Unique to Pregnancy in a US Community: A Population-Based Study. Clin Gastroenterol Hepatol 14:287-94.e1-2
Heimbach, Julie K; Hirose, Ryutaro; Stock, Peter G et al. (2015) Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology 61:1643-50
Allen, Alina M; Kim, W Ray; Larson, Joseph J et al. (2015) Serum Cystatin C as an Indicator of Renal Function and Mortality in Liver Transplant Recipients. Transplantation 99:1431-5
Allen, Alina M; Kim, W Ray; Therneau, Terry M et al. (2015) Reply to: ""Chronic kidney disease after liver transplantation"". J Hepatol 62:244-5
Angeli, Paolo; Gines, Pere; Wong, Florence et al. (2015) Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 62:968-74
Allen, Alina M; Kim, W Ray; Heimbach, Julie K et al. (2015) Reply to: ""Chronic kidney disease (CKD) and NAFLD: time for awareness and screening"". J Hepatol 62:984-5
Allen, Alina M; Kim, W Ray; Therneau, Terry M et al. (2014) Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate. J Hepatol 61:286-92
Kim, Bo Hyun; Park, Joong-Won; Nam, Byung-Ho et al. (2014) Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single-centre cohort study. Liver Int 34:e317-23
Allen, A M; Kim, W R; Xiong, H et al. (2014) Survival of recipients of livers from donation after circulatory death who are relisted and undergo retransplant for graft failure. Am J Transplant 14:1120-8

Showing the most recent 10 out of 82 publications